Rosvamac F Tablets contain Rosuvastatin and Fenofibrate which are synthetic lipid-altering agents.
Dosage Form
Tablet
Route of Administration
Oral
Composition
Each film-coated tablet contains:
Rosuvastatin Calcium Eq. to Rosuvastatin I.P. 10 mg
Fenofibrate (Micronised) I.P. 160 mg
Excipients q.s.
Indications
Rosvamac F Tablets are indicated as an adjunct to diet for reducing elevated cholesterol and triglyceride levels, managing primary hyperlipidemia, mixed dyslipidemia, familial hypercholesterolemia, hypertriglyceridemia, primary dysbetalipoproteinemia, and homozygous familial hypercholesterolemia. It is also used to slow the progression of atherosclerosis and help prevent cardiovascular disease.
Storage
Store at a temperature not exceeding 25°C, protected from light and moisture.
Precautions
Rosvamac F Tablets should be used with caution in patients with liver disease, kidney impairment, gallbladder disorders, or a history of muscle-related conditions. Regular monitoring of liver function, kidney function, and lipid levels may be required during treatment. The medicine should not be used during pregnancy or breastfeeding and should only be taken under medical supervision.
Presentation
10 × 10 Tablets.
GLOBAL HORIZONS
Your Efforts Extended Through a Partnership That's Better Together
